Table II. Characteristics of the headache and headache-related symptoms.
|
|
Entire study sample
(n = 238)
|
COVID-19 related- headache
(n = 143)
|
COVID-19 vaccine-related headache
(n = 95)
|
FDR-corrected p-value
|
Duration of headache (hours), median [IQR]
|
7 [3-24]
|
12 [3-24]
|
6 [2-12]
|
0.007
|
Intensity of headache, median [IQR]
|
7 [6-8]
|
7 [6-8]
|
7 [5-7]
|
0.191
|
Disability of headache, median [IQR]
|
50% [20-70%]
|
50% [20-70%]
|
60% [20-70%]
|
0.446
|
Holocranial headache, n (%)
|
197 (82.8%)
|
117 (81.8%)
|
80 (84.2%)
|
0.902
|
Hemicranial headache, n (%)
|
53 (22.3%)
|
26 (18.2%)
|
27 (28.4%)
|
0.189
|
Frontal localization, n (%)
|
109 (45.8%)
|
66 (46.2%)
|
43 (45.3%)
|
0.999
|
Temporal localization, n (%)
|
79 (33.2%)
|
45 (31.5%)
|
34 (35.8%)
|
0.77
|
Parietal localization, n (%)
|
46 (19.3%)
|
17 (11.9%)
|
29 (30.5%)
|
0.005
|
Occipital localization, n (%)
|
33 (13.9%)
|
21 (14.7%)
|
12 (12.6%)
|
0.919
|
Periocular localization, n (%)
|
29 (12.2%)
|
22 (15.4%)
|
7 (7.4%)
|
0.194
|
Vertex localization, n (%)
|
15 (6.3%)
|
7 (4.9%)
|
8 (8.4%)
|
0.508
|
Cervical localization, n (%)
|
13 (5.5%)
|
8 (5.6%)
|
5 (5.3%)
|
0.999
|
Pressing quality, n (%)
|
181 (76.1%)
|
110 (76.9%)
|
71 (74.7%)
|
0.953
|
Throbbing quality, n (%)
|
33 (13.9%)
|
20 (14.0%)
|
13 (13.7%)
|
0.999
|
Photophobia, n (%)
|
78 (32.8%)
|
39 (27.3%)
|
39 (41.1%)
|
0.116
|
Phonophobia, n (%)
|
95 (39.9%)
|
43 (30.1%)
|
52 (54.7%)
|
<0.001
|
Osmophobia, n (%)
|
9 (3.8%)
|
6 (4.2%)
|
3 (3.2%)
|
0.999
|
Nausea, n (%)
|
30 (12.6%)
|
18 (12.6%)
|
12 (12.6%)
|
0.856
|
Vomiting, n (%)
|
11 (4.6%)
|
7 (4.9%)
|
4 (4.2%)
|
0.999
|
Worsening by physical activity, n (%)
|
172 (72.3%)
|
97 (67.8%)
|
75 (78.9%)
|
0.203
|
Worsening by head movement, n (%)
|
102 (42.9%)
|
45 (31.5%)
|
57 (60%)
|
<0.001
|
Worsening by eye movement, n (%)
|
63 (26.5%)
|
24 (16.8%)
|
39 (41.1%)
|
<0.001
|
FDR: false discovery rate; IQR: inter-quartile range.
|